Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Abrams

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|September 25, 2014
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinomaLipika Goyal, Raymond C Wadlow, Lawrence S Blaszkowsky, et al.
BMJ Open Sport & Exercise Medicine|June 20, 2022
Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility studyJustin C Brown, Elizabeth Brighton, Nancy Campbell, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2020
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract CancerLipika Goyal, Cynthia Sirard, Michael Schrag, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
Cancer|February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaLipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Cancer|May 4, 2011
Phase 1/2 study of everolimus in advanced hepatocellular carcinomaAndrew X Zhu, Thomas A Abrams, Rebecca Miksad, et al.
Investigational New Drugs|April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsDouglas A Rubinson, Howard S Hochster, David P Ryan, et al.
British Journal of Cancer|June 17, 2022
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohortsXiao Luo, Wanshui Yang, Amit D Joshi, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|September 25, 2014
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinomaLipika Goyal, Raymond C Wadlow, Lawrence S Blaszkowsky, et al.
BMJ Open Sport & Exercise Medicine|June 20, 2022
Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility studyJustin C Brown, Elizabeth Brighton, Nancy Campbell, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2020
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract CancerLipika Goyal, Cynthia Sirard, Michael Schrag, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
Cancer|February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaLipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Cancer|May 4, 2011
Phase 1/2 study of everolimus in advanced hepatocellular carcinomaAndrew X Zhu, Thomas A Abrams, Rebecca Miksad, et al.
Investigational New Drugs|April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsDouglas A Rubinson, Howard S Hochster, David P Ryan, et al.
British Journal of Cancer|June 17, 2022
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohortsXiao Luo, Wanshui Yang, Amit D Joshi, et al.
Pageof 5